Trends in Multiple Sclerosis Therapy Examined in New Insightful FirstWord …San Francisco Chronicle (press release)… beta-1b; Novartis) Forecast; BG-12 (dimethyl fumarate; Biogen) Forecast; Aubagio (teriflunomide; Sanofi) Forecast; Laquinimod (Teva/…

Tysabri Taking Biogen Idec To New HighsForbesFounded in 1985, Biogen has several candidates in its pipeline, including BG-12 (multiple sclerosis), daclizumab (multiple sclerosis), Factor VIII (hemophilia A) and Factor IX (hemophilia B) among others. So…

Biogen Idec – MomentumNASDAQFounded in 1985, Biogen has several candidates in its pipeline, including BG-12 (multiple sclerosis), daclizumab (multiple sclerosis), Factor VIII (hemophilia A) and Factor IX (hemophilia B) among others. Want More of Our Be…

Positive trial results for Biogen Idec's MS drug BG-12The Pharma LetterIn fact, interest in BG-12, along with Biogen Idec's PEG-Avonex, Abbott/Biogen Idec's daclizumab and Roche/Genentech's ocrelizumab, has increased significantly compa…

I3 Analytics' ClinicalTrials Navigator Sees A New Dawn For Multiple Sclerosis …Daily MarketsIn addition to the aforementioned drugs that are pending FDA approval, there are several promising therapies in the later stages of clinical development a…

i3 Analytics' ClinicalTrials Navigator Sees A New Dawn for Multiple Sclerosis …PR Web (press release)In addition to the aforementioned drugs that are pending FDA approval, there are several promising therapies in the later stages of clinical deve…

Search local inventory, coupons and moreThe Herald | HeraldOnline.comPatient profiles for the seven DMAs in late clinical development (teriflunomide, BG-12, alemtuzumab, PEG-Avonex, daclizumab, laquinimod, ocrelizumab) are also characterized. About Bio…

New BioTrends Chart Audit Measures the Impact of Recent Multiple Sclerosis …MarketWatch (press release)Patient profiles for the seven DMAs in late clinical development (teriflunomide, BG-12, alemtuzumab, PEG-Avonex, daclizumab, laquinimod, ocrelizuma…

Elan unlikely target for Biogen given latter's focus on MS drug BG-12Financial TimesIn addition, the company is advancing daclizumab, an IL-2R antibody, in what will be the largest MS study ever conducted. Data is expected in 2014. On 13 August 201…

Regulus, Biogen Idec Partner on MS BiomarkersGenetic Engineering NewsBG-12 (dimethyl fumarate) is a small molecule immune modulator currently undergoing regulatory review. A PEGylated interferon beta-1a is currently in Phase III development for relapsi…